Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vericel Corp Ord (VCEL)
Assess today's live Vericel Corp Ord (VCEL) share price, performance and insights using our live NASDAQ: VCEL stock exchange data.
Analyse the historical data and Vericel Corp Ord share price performance charts on this page. Our technical summary section provides analysis on Vericel Corp Ord share price buy/sell indicators using real-time data (or discuss the Vericel Corp Ord (VCEL) stock price today with other investors in the Vericel Corp Ord NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ VCEL share price (ISIN: US92346J1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Vericel Corp Ord Share Price Today?
The Vericel Corp Ord share price today is 37.38.
What Is the Stock Symbol for Vericel Corp Ord
The stock symbol (or 'ticker') for Vericel Corp Ord is "VCEL."
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
Is Vericel Corp Ord a Good Stock to Buy?
Determining whether Vericel Corp Ord—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Vericel Corp Ord share price performance charts on this page. Our technical summary section provides analysis on Vericel Corp Ord share price buy/sell indicators using real-time data (or discuss the Vericel Corp Ord (VCEL) stock price today with other investors in the Vericel Corp Ord NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ VCEL share price (ISIN: US92346J1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Vericel Corp Ord Share Price Today?
The Vericel Corp Ord share price today is 37.38.
What Is the Stock Symbol for Vericel Corp Ord
The stock symbol (or 'ticker') for Vericel Corp Ord is "VCEL."
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
Is Vericel Corp Ord a Good Stock to Buy?
Determining whether Vericel Corp Ord—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.74
37.62
52 wk Range
29.24
63.00
VCEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.7437.62
52 wk Range
29.2463.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VCEL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
55.00
Upside
+47.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Vericel Corp For: 3 December
- Investing.com
- Form 144 Vericel Corp For: 2 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Vericel Corp Ord Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corp Ord SWOT Analysis
MACI Arthro Triumph | Vericel's FDA approval for MACI Arthro expands its cartilage repair market, positioning it as the only arthroscopic biologic solution for knee defects up to 4cm2 |
Market Expansion Strategy | Delve into Vericel's plan to grow its surgeon base from 5,000 to 7,000, targeting high-volume arthroscopic specialists to drive MACI Arthro adoption |
Revenue Potential | Explore how MACI Arthro could significantly boost Vericel's revenues by penetrating the 2-4cm² condyle defect market, potentially doubling total MACI sales |
Competitive Edge | Learn about Vericel's strengthened position in the $3 billion cartilage repair market, with analysts setting a price target of $57.00 for August 2024 |
Vericel Corp Ord Earnings Call Summary for Q3/2025
- Vericel reported record Q3 revenue of $67.5M with EPS of $0.10, significantly beating forecasts of $64.56M and -$0.01 respectively, driving a 12.1% pre-market stock surge
- MACI product revenue grew 25% year-over-year while burn care segment increased 21% sequentially, contributing to gross profit of nearly $50M (73.5% of revenue)
- The company ended Q3 with $185M in cash and investments, generating record operating cash flow of $22.1M and adjusted EBITDA of $17M (70% increase YoY)
- Management raised full-year revenue guidance to $272-276M, projecting MACI revenue growth in the low 20% range with targets for high 70% gross margins by 2029
- CEO Nick Colangelo highlighted MACI's growth from a $30M product to nearly $250M over ten years, with CFO Joe Mara emphasizing 'significant' financial trajectory through 2026
Last Updated: 06/11/2025, 16:00
Read Full TranscriptCompare VCEL to Peers and Sector
Metrics to compare | VCEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCELPeersSector | |
|---|---|---|---|---|
P/E Ratio | 144.5x | −2.2x | −0.6x | |
PEG Ratio | 0.61 | 0.13 | 0.00 | |
Price/Book | 5.9x | 2.9x | 2.6x | |
Price / LTM Sales | 7.3x | 2.3x | 3.2x | |
Upside (Analyst Target) | 47.1% | 92.4% | 41.8% | |
Fair Value Upside | Unlock | 3.1% | 5.1% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 55.00
(+47.14% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
0.10 / -0.01
Revenue / Forecast
67.50M / 64.56M
People Also Watch
FAQ
What Is the Vericel Corp Ord (VCEL) Share Price Today?
The live Vericel Corp Ord share price today is 37.38
What Stock Exchange Does Vericel Corp Ord (VCEL) Trade On?
Vericel Corp Ord is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Vericel Corp Ord?
The stock symbol (also called a 'ticker') for Vericel Corp Ord is "VCEL."
What Is the Current Vericel Corp Ord Market Cap?
As of today, Vericel Corp Ord market capitalisation is 1.89B.
What Is Vericel Corp Ord's (VCEL) Earnings Per Share (TTM)?
The Vericel Corp Ord EPS is currently 0.25 (Trailing Twelve Months).
When Is the Next Vericel Corp Ord Earnings Date?
Vericel Corp Ord's next earnings report will be released on 26 Feb 2026.
Is VCEL a Buy or Sell From a Technical Analyst Perspective?
Based on today's Vericel Corp Ord moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Vericel Corp Ord Stock Split?
Vericel Corp Ord has split 2 times. (See the VCEL stock split history page for full effective split date and price information.)
How Many Employees Does Vericel Corp Ord Have?
Vericel Corp Ord has 357 employees.
What is the current trading status of Vericel Corp Ord (VCEL)?
As of 24 Dec 2025, Vericel Corp Ord (VCEL) is trading at a price of 37.38, with a previous close of 37.37. The stock has fluctuated within a day range of 36.74 to 37.62, while its 52-week range spans from 29.24 to 63.00.
What Is Vericel Corp Ord (VCEL) Price Target According to Analysts?
The average 12-month price target for Vericel Corp Ord is USD55, with a high estimate of USD62 and a low estimate of USD45. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +47.14% Upside potential.
What Is the VCEL Premarket Price?
VCEL's last pre-market stock price is 37.47. The pre-market share volume is 1,050.00, and the stock has decreased by 0.10, or 0.27%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.